Andrew Badrot, CEO of C2 PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond
Chief Executive Officer and Founder, C2 PHARMA
A: In one word: Brazil. We see Brazil as a bourgeoning country to export APIs. Brazil already manufactures APIs for the local consumption. We see Brazil exporting its APIs and becoming an API manufacturing powerhouse supplying the global pharmaceutical industry over the next 10 years. Among the key strengths of Brazil are ANVISA standards, which are very high and recognized by the European Union, strong local API know-how, a talent pool of chemists and engineers and a competitive cost structure. C2 PHARMA is investing heavily to collaborate with Brazilian companies to market their APIs outside Brazil.
Click here to view the article.